OpenURL Connection Search

Select item for more details and to access through your institution.

Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
Published in:
PLoS Pathogens, 2022, v. 18, n. 4, p. 1, doi. 10.1371/journal.ppat.1009925
By:
- Van Rompay, Koen K. A.;
- Olstad, Katherine J.;
- Sammak, Rebecca L.;
- Dutra, Joseph;
- Watanabe, Jennifer K.;
- Usachenko, Jodie L.;
- Immareddy, Ramya;
- Roh, Jamin W.;
- Verma, Anil;
- Shaan Lakshmanappa, Yashavanth;
- Schmidt, Brian A.;
- Di Germanio, Clara;
- Rizvi, Nabeela;
- Liu, Hongwei;
- Ma, Zhong-Min;
- Stone, Mars;
- Simmons, Graham;
- Dumont, Larry J.;
- Allen, A. Mark;
- Lockwood, Sarah
Publication type:
Article
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.
Published in:
PLoS Pathogens, 2021, v. 17, n. 7, p. 1, doi. 10.1371/journal.ppat.1009688
By:
- Van Rompay, Koen K. A.;
- Olstad, Katherine J.;
- Sammak, Rebecca L.;
- Dutra, Joseph;
- Watanabe, Jennifer K.;
- Usachenko, Jodie L.;
- Immareddy, Ramya;
- Verma, Anil;
- Shaan Lakshmanappa, Yashavanth;
- Schmidt, Brian A.;
- Roh, Jamin W.;
- Elizaldi, Sonny R.;
- Allen, A. Mark;
- Muecksch, Frauke;
- Lorenzi, Julio C. C.;
- Lockwood, Sarah;
- Pollard, Rachel E.;
- Yee, JoAnn L.;
- Nham, Peter B.;
- Ardeshir, Amir
Publication type:
Article
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates.
Published in:
NPJ Vaccines, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41541-023-00743-6
By:
- Fowler, Alexandra;
- Van Rompay, Koen K. A.;
- Sampson, Maureen;
- Leo, Javier;
- Watanabe, Jennifer K.;
- Usachenko, Jodie L.;
- Immareddy, Ramya;
- Lovato, Debbie M.;
- Schiller, John T.;
- Remaley, Alan T.;
- Chackerian, Bryce
Publication type:
Article
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.
Published in:
Science Translational Medicine, 2023, v. 15, n. 685, p. 1, doi. 10.1126/scitranslmed.add6383
By:
- Milligan, Emma C.;
- Olstad, Katherine;
- Williams, Caitlin A.;
- Mallory, Michael;
- Cano, Patricio;
- Cross, Kaitlyn A.;
- Munt, Jennifer E.;
- Garrido, Carolina;
- Lindesmith, Lisa;
- Watanabe, Jennifer;
- Usachenko, Jodie L.;
- Hopkins, Lincoln;
- Immareddy, Ramya;
- Shaan Lakshmanappa, Yashavanth;
- Elizaldi, Sonny R.;
- Roh, Jamin W.;
- Sammak, Rebecca L.;
- Pollard, Rachel E.;
- Yee, JoAnn L.;
- Herbek, Savannah
Publication type:
Article

Found: 4

Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.

Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.

A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates.

Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.